Mitochondrial decline is a real part of ageing. The pills aimed at it mostly disappoint.

Mitochondria, the structures that turn food and oxygen into usable energy, work less well as the body ages — and that decline is a genuine feature of biological ageing, not a marketing invention [s1]. But the compounds sold or trialled to counter it tell a more sobering story: in human studies, mitochondria-targeted supplements and drugs have produced small or borderline effects, and on the endpoints that matter most they keep returning null [s2][s4].

The premise is solid. The most cited catalogue of ageing biology lists mitochondrial dysfunction as one of twelve interconnected hallmarks, defined by the same three tests applied to each: it appears with age, accelerating it experimentally speeds ageing, and reversing it is a plausible therapeutic target [s1]. Ageing mitochondria generate energy less efficiently, leak more reactive oxygen species, and are cleared and replaced more sluggishly. That biology is why so many longevity products — from antioxidants to NAD precursors to microbiome metabolites — converge on the mitochondrion. The question is not whether the target is real but whether hitting it does anything measurable in people.

Urolithin A: endurance up, the headline numbers flat

Urolithin A, a compound the gut microbiome makes from pomegranates and nuts and now sold as a supplement, is meant to work by stimulating mitophagy — the recycling of worn-out mitochondria. A double-blind randomised trial gave 1,000 mg a day or placebo to 66 adults aged 65 to 90 (mean age 71.7, three-quarters of them women) for four months [s2]. On its two primary endpoints — distance walked in six minutes and maximal energy (ATP) production measured in muscle — the supplement showed no significant improvement over placebo; the six-minute walk rose 60.8 metres on urolithin A versus 42.5 on placebo, a gap within the noise [s2].

Where it did register was on secondary measures: muscle endurance, counted as contractions to fatigue in a hand and a leg muscle, improved significantly at two months, and several blood markers of mitochondrial and cellular stress fell [s2]. That is a real but modest signal, and it comes with a caveat readers should weigh — the compound's commercial developer was involved in the study, the kind of interest that warrants independent replication. A separate meta-analysis pooling five small urolithin A trials reached an inconclusive verdict on muscle benefit, which is the fair summary.

MitoQ: a genuine vascular effect, a narrow one

A cleaner positive result comes from MitoQ, an antioxidant engineered to accumulate inside mitochondria. In a randomised crossover study, 20 healthy older adults (aged 60 to 79) with impaired blood-vessel function took 20 mg a day for six weeks [s3]. Brachial-artery flow-mediated dilation — a standard measure of how well arteries relax — was 42% higher after MitoQ than after placebo, aortic stiffness was lower in the subset who started stiffer, and a marker of oxidative stress fell [s3].

That is a well-conducted trial with a plausible mechanism, and it is worth crediting. But its limits are equally clear: 20 people, six weeks, and a physiological measurement rather than a health outcome. Improving a vascular marker is a promising lead, not evidence that a supplement prevents heart attacks or extends life — the distance between the two is exactly where most longevity claims fall apart.

Elamipretide: the hardest test, and a near-miss

The most demanding test of mitochondrial therapy is not in healthy ageing but in primary mitochondrial myopathy, an inherited disease in which mitochondria genuinely fail. Elamipretide, a drug that targets a key mitochondrial membrane lipid, was put through the phase 3 MMPOWER-3 trial — and, as its own follow-up analysis concedes, it "did not demonstrate a significant benefit" across a genetically mixed population of patients [s4]. A pre-specified subgroup with defects in the machinery that copies mitochondrial DNA did better: their six-minute walk distance improved by 25.2 metres on the drug versus 2.0 on placebo — but even that difference only trended toward significance (p=0.06) and came from a slice of the trial [s4]. If a targeted drug struggles to help patients whose mitochondria are demonstrably broken, expectations for boosting healthy mitochondria with an over-the-counter capsule should be set accordingly.

What it adds up to

The mitochondrial theory of ageing rests on sound biology: the organelle really does decline, and it is a legitimate hallmark of the process [s1]. What the human evidence does not yet support is the next step — that swallowing a mitochondria-targeted compound meaningfully slows ageing. The best results so far are a shift in a vascular marker in 20 people [s3], an endurance gain that a pooled analysis could not confirm [s2], and a subgroup near-miss in a drug trial that missed overall [s4]. That pattern — mechanistically appealing, clinically thin — is the same one that recurs across the NAD-boosting supplements and autophagy-targeting compounds that share the mitochondrion as a target. The hallmark is real; the pills aimed at it have not earned their claims.